<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118272</url>
  </required_header>
  <id_info>
    <org_study_id>K-06 Physica KR</org_study_id>
    <nct_id>NCT02118272</nct_id>
  </id_info>
  <brief_title>Clinical Study Evaluating the Outcomes of a New Knee System With a Physiological Rollback Mechanism</brief_title>
  <acronym>K-06</acronym>
  <official_title>A Multicentre, Prospective Clinical Study Evaluating the Outcomes of a New Knee System With a Physiological Rollback Mechanism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the clinical, radiographic and patient-reported outcome&#xD;
      measures (PROMs) after total knee replacement with Physica KR, define the survivorship of the&#xD;
      implants and identify possible risk factors that may lead to failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Society Clinical Rating System (KSS)</measure>
    <time_frame>From baseline to 5 year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>From baseline to 5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Knee Score (OKS)</measure>
    <time_frame>From baseline to 5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction Visual Analogue Scale (VAS)</measure>
    <time_frame>From baseline to 5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate of the implant</measure>
    <time_frame>at 3 and 5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE/SAE, ADE/SADE</measure>
    <time_frame>From baseline to 5 year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forgotten Joint score (FJS)</measure>
    <time_frame>From baseline to 5 year follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Primary Total Knee Replacement</condition>
  <arm_group>
    <arm_group_label>Physica KR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Physica KR</intervention_name>
    <arm_group_label>Physica KR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and females&#xD;
&#xD;
          2. Age 22-80 years&#xD;
&#xD;
          3. Any race&#xD;
&#xD;
          4. Ambulatory patients&#xD;
&#xD;
          5. Patients who have a medical condition with over 5 years of life expectancy&#xD;
&#xD;
          6. Patients requiring knee prosthesis, suitable for the use of Physica KR&#xD;
&#xD;
          7. Patients with painful primary knee osteoarthritis&#xD;
&#xD;
          8. Patients with painful secondary knee osteoarthritis&#xD;
&#xD;
          9. Patients who are suffering from inflammatory arthritis (e.g. rheumatoid arthritis)&#xD;
&#xD;
         10. Patients who have undamaged and functional collateral and posterior cruciate ligaments&#xD;
&#xD;
         11. Patients with a flexion greater than or equal to 90째 on the affected side&#xD;
&#xD;
         12. Patients with a fixed flexion contracture less than 10째&#xD;
&#xD;
         13. Patients who understand the conditions of the study and are willing and able to comply&#xD;
             with the prescribed rehabilitation and to perform all scheduled follow-up visits&#xD;
&#xD;
         14. Patients who have signed the Ethics Committee approved study-specific Informed Consent&#xD;
             Form prior to the surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Obese patients with BMI above 35 kg/m2 (severe obesity)&#xD;
&#xD;
          2. Previous partial knee replacement (unilateral, bicompartimental or patellofemoral&#xD;
             joint replacement), patellectomy, high tibial osteotomy or femoral osteotomy in the&#xD;
             affected knee&#xD;
&#xD;
          3. Primary Total Knee Replacement (TKR) in the affected knee&#xD;
&#xD;
          4. Varus or Valgus deformity greater than 20째&#xD;
&#xD;
          5. Patients with a fixed flexion contracture greater than 10째&#xD;
&#xD;
          6. Previous knee replacement on the contralateral side within the last year and whose&#xD;
             outcome is achieving an KSS&lt; 70 points&#xD;
&#xD;
          7. Patients with symptomatic OA of the hips, spine, ankles, if it can interfere with the&#xD;
             evaluation of the target knee&#xD;
&#xD;
          8. Patients with active or any suspected infection (on the affected knee or systemic)&#xD;
&#xD;
          9. Muscular insufficiency or absence of muscoligamentous supporting structures required&#xD;
             for adequate soft tissue balance&#xD;
&#xD;
         10. Patients with known or suspicious metal hypersensitivity&#xD;
&#xD;
         11. Recurrent medical history of severe allergic or immune-mediated reactions&#xD;
&#xD;
         12. Vascular insufficiency of lower limbs severe enough to interfere with the study&#xD;
             evaluation&#xD;
&#xD;
         13. Current treatment or treatment within the previous 2 years before the screening visit&#xD;
             for malignant and life-threatening non-malignant disorders&#xD;
&#xD;
         14. Any clinically significant pathology based on clinical history that the Investigator&#xD;
             feels may affect the study evaluation&#xD;
&#xD;
         15. Any intercurrent chronic disease or condition that may interfere with the completion&#xD;
             of the 5-year follow-up, such as liver disease, severe coronary disease, alcohol or&#xD;
             drug abuse, disordered mental state, or other clinically significant condition&#xD;
&#xD;
         16. Patients who have significant neurological or musculoskeletal disorders or disease&#xD;
             that may adversely affect gait and compromise functional recovery and evaluation&#xD;
&#xD;
         17. Patients who have neuromuscular or neurosensory deficit which would limit the ability&#xD;
             to assess the performance of the device&#xD;
&#xD;
         18. Patients with systemic or metabolic disorders leading to progressive bone&#xD;
             deterioration&#xD;
&#xD;
         19. Patients who have a medical condition with less 5 years of life expectancy&#xD;
&#xD;
         20. Previous organ transplant surgery&#xD;
&#xD;
         21. Any psychiatric illness that would prevent comprehension of the details and nature of&#xD;
             the study&#xD;
&#xD;
         22. Participation in any experimental drug/device study within the 6 months prior to the&#xD;
             screening visit&#xD;
&#xD;
         23. Female patients who are pregnant, nursing, or planning a pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliero-universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Bournemouth Hospital, NHS Foundation Trust</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorset County Hospital NHS Foundation Trust</name>
      <address>
        <city>Dorchester</city>
        <state>Dorset</state>
        <zip>DT1 2JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

